Regenxbio inks deal with AbbVie to pursue development of RGX-314

Regenxbio (NSDQ:RGNX) has closed a license agreement with AbbVie (NYSE:ABBV) to develop RGX-314, a vascular endothelial growth factor inhibitor.

The drug has been the focus of Phase 2 and Phase 3 trials exploring its potential in wet age-related macular degeneration (AMD) and diabetic retinopathy.

AbbVie will make an upfront payment to Regenxbio of $370 million and could pay an additional $1.38 billion if the drug candidate meets proposed development, regulatory and commercial milestones.

In the agreement, Regenxbio will focus on overseeing the completion of ongoing trials related to the RGX-314. The two companies will partner and split the cost of additional studies related to the drug candidate.

The two companies intend to perform an additional pivotal trial testing subretinal delivery to treat wet AMD and future trials.

AbbVie plans on leading clinical development and commercialization of the drug.

In October, Regenxbio released p…

Read more
  • 0

EyePoint Pharmaceuticals’ CEO on treating serious eye disorders and female leadership in life sciences

EyePoint Pharmaceuticals (NASDAQ: EYPT) specializes in creating ocular products for serious eye disorders. The company has developed five FDA-approved sustained-release treatments in ophthalmology. The company’s preclinical development program is focused on drug candidates to treat wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases.

The company was formed in 2018 after pSivida announced acquired Icon Bioscience.

To learn more about the company, we interviewed EyePoint Pharmaceuticals’ president and CEO, Nancy S. Lurker, who is also an advisor to Novo Nordisk and serves on the board of directors for the company Aquestive Therapeutics.

In the following interview, Lurker touches on what inspires her as the CEO of EyePoint while also providing advice for women interested in pursuing leadership roles within the life sciences industry.

Nancy Lurker

Preventing bli…

Read more
  • 0